Fecal microbiota transplant in immunocompromised patients: Encouraging results in a vulnarable population.

Definitely, fecal microbiota transplantation (FMT) is a promising research area in disorders with dysbiosis. It is not a novel therapy, however recent advances in gut microbiota research enabled physicians to practice FMT in a more scientific basis. One of the main drawbacks in FMT is the safety and adverse events, which are not thoroughly documented in large series. Among these, immunocompromised (IC) patients are the most feared and neglected population. Actually, data regarding the safety of FMT in this vulnerable population gives a more concrete confidence to physicians demanding FMT.